We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Beats on Q2 Earnings and Revenues
Read MoreHide Full Article
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm and Neuro, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #4 (Sell) but that could change following its second-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Boston Scientific’s adjusted earnings of 41 cents per share surpasses the Zacks Consensus Estimate of 34 cents per share.
Revenues: Boston Scientific posted revenues of $2.49 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.47 billion.
Boston Scientific Corporation Price and EPS Surprise
Key Stats: In the second-quarter 2018, Boston Scientific’s Cardiovascular segment revenues increased 10% on a reported basis to $965 million, while Rhythm and Neuro segment’s revenue grew 10.8%, totaling $775 million. Also, revenues from the MedSurg segment improved 10.4% to $751 million.
Major Factors: Boston Scientific has posted impressive second quarter results by delivering revenue growth across all segments. Moreover, the company received FDA approval, CE Mark and Japanese Pharmaceuticals and Medical Devices Agency approval for its rotational atherectomy technology — the ROTAPRO Rotational Atherectomy System. Boston Scientific has also issued guidance for third quarter 2018 and updated full-year 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Boston Scientific earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Boston Scientific (BSX) Beats on Q2 Earnings and Revenues
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm and Neuro, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #4 (Sell) but that could change following its second-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Boston Scientific’s adjusted earnings of 41 cents per share surpasses the Zacks Consensus Estimate of 34 cents per share.
Revenues: Boston Scientific posted revenues of $2.49 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.47 billion.
Boston Scientific Corporation Price and EPS Surprise
Boston Scientific Corporation Price and EPS Surprise | Boston Scientific Corporation Quote
Key Stats: In the second-quarter 2018, Boston Scientific’s Cardiovascular segment revenues increased 10% on a reported basis to $965 million, while Rhythm and Neuro segment’s revenue grew 10.8%, totaling $775 million. Also, revenues from the MedSurg segment improved 10.4% to $751 million.
Major Factors: Boston Scientific has posted impressive second quarter results by delivering revenue growth across all segments. Moreover, the company received FDA approval, CE Mark and Japanese Pharmaceuticals and Medical Devices Agency approval for its rotational atherectomy technology — the ROTAPRO Rotational Atherectomy System. Boston Scientific has also issued guidance for third quarter 2018 and updated full-year 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Boston Scientific earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>